Q1 Earnings vs. Estimates
EPS: Reported $1.79, beating the $1.67 consensus by $0.12.
Revenue: $9.89 B vs. $10.99 B estimate—a 10% shortfall.
Key Drivers: Specialty care and vaccines drove margin strength, but generics and consumer health underperformed.
Stock Performance and Analyst Sentiment
Closing Price: $53.02 per ADR
Momentum: +1.0% over 3 months; +7.4% over 12 months
Analyst Revisions: Mixed—positive EPS revisions offset by cautious revenue outlook tweaks.
Financial Health Snapshot
Sanofi’s robust balance sheet underpins its resilience:
Profit Margins: Holding up despite top-line pressures
Leverage: Moderate debt with ample liquidity
Outlook and Investor Takeaways
Q2 Guidance: Look for updated sales forecasts on May 7 earnings call.
Pipeline Catalysts: Late-stage readouts in diabetes and immunology.
Cost Synergies: Progress on recent M&A integrations could bolster margins.
Track Sanofi’s Past Earnings and Market Reactions
For detailed historical EPS and revenue surprises—and how Sanofi’s stock reacted—use the? Historical Earnings APIfrom Financial Modeling Prep. This API delivers past earnings versus estimates, enabling you to analyze patterns in consensus beats, misses, and stock price responses.
